These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32694355)

  • 1. Serious Opportunistic Lower Respiratory Tract Infections in Pediatric Rheumatic Diseases During Treatment With Biologics.
    Ogstrup AK; Spannow AH; Holm M; Rubak S; Veirum JE; Glerup M; Herlin T
    J Clin Rheumatol; 2021 Dec; 27(8S):S387-S391. PubMed ID: 32694355
    [No Abstract]   [Full Text] [Related]  

  • 2. Opportunistic Infections in Biological Therapy, Risk and Prevention.
    Bryant PA; Baddley JW
    Rheum Dis Clin North Am; 2017 Feb; 43(1):27-41. PubMed ID: 27890172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
    Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biologics].
    Kalden JR
    Z Rheumatol; 2016 Aug; 75(6):604-10. PubMed ID: 27365024
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biologics and cardiovascular risk].
    Tarner IH; Müller-Ladner U; Hamm C
    Z Rheumatol; 2010 Oct; 69(8):702-6, 708-11. PubMed ID: 20862482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How dangerous are norovirus infections in patients with rheumatic diseases treated with biologics and DMARDs? Follow-up on a local outbreak and comparison with a control cohort.
    Fiehn C; Miehle N
    Ann Rheum Dis; 2014 Apr; 73(4):786-7. PubMed ID: 24276367
    [No Abstract]   [Full Text] [Related]  

  • 10. [Infections during antirheumatic treatment].
    Kneitz C
    Dtsch Med Wochenschr; 2014 Aug; 139(31-32):1593-5. PubMed ID: 25076314
    [No Abstract]   [Full Text] [Related]  

  • 11. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
    Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
    Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.
    Geri G; Dadoun S; Bui T; Del Castillo Pinol N; Paternotte S; Dougados M; Gossec L
    BMC Infect Dis; 2011 Nov; 11():304. PubMed ID: 22046967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients.
    Sebastiani M; Manfredi A; Cassone G; Sandri G; Cerri S; Ferri C
    Clin Exp Rheumatol; 2017; 35(3):542. PubMed ID: 28516882
    [No Abstract]   [Full Text] [Related]  

  • 14. Malignancy and the Risks of Biologic Therapies: Current Status.
    Seror R; Mariette X
    Rheum Dis Clin North Am; 2017 Feb; 43(1):43-64. PubMed ID: 27890173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
    Furst DE; Keystone EC; Kirkham B; Kavanaugh A; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Burmester GR; Braun J; Emery P; Winthrop K; Bresnihan B; De Benedetti F; Dörner T; Gibofsky A; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii2-25. PubMed ID: 19022808
    [No Abstract]   [Full Text] [Related]  

  • 16. Infection risk and biologics: current update.
    Wallis D
    Curr Opin Rheumatol; 2014 Jul; 26(4):404-9. PubMed ID: 24827752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries.
    Zavada J; Dixon WG; Askling J;
    Ann Rheum Dis; 2014 Mar; 73(3):628. PubMed ID: 24058015
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
    Wendling D; Di Martino V; Herbein G
    J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
    [No Abstract]   [Full Text] [Related]  

  • 19. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety issues of biologics in pregnant patients with rheumatic diseases.
    Ostensen M
    Ann N Y Acad Sci; 2014 May; 1317():32-8. PubMed ID: 24840548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.